Why the study?
Does mPGES-1 inhibition reduce cardiovascular inflammation and atherogenesis without the adverse cardiovascular effects seen with COX-2 inhibitors?
Does mPGES-1 inhibition reduce cardiovascular inflammation and atherogenesis without the adverse cardiovascular effects seen with COX-2 inhibitors?
mPGES-1 inhibitors demonstrate therapeutic potential for cardiovascular inflammatory syndromes like atherosclerosis and aortic aneurysm without the thrombotic risks associated with COX-2 inhibitors.
Answers are grounded in this paper and cite their sources.
mPGES-1 inhibition merits human trials for atherosclerosis; leaves open whether mouse benefits translate without COX-2 risks.
Prostaglandins (PGs), particularly PGE2 and prostacyclin (PGI2), are potent mediators of pain and inflammation. Both atherosclerosis and aortic aneurysm exhibit the hallmarks of inflammation. However, randomized trials of inhibitors of PG synthesis--nonsteroidal anti-inflammatory drugs--reveal that they predispose to cardiovascular risk. This appears to be consequent to inhibition of PGI2 and PGE2 formed by cyclooxygenase-2 (COX-2). Inhibitors of microsomal PGE synthase-1 (mPGES-1) are being developed for relief of pain and interest has focused on their potential impact on the cardiovascular system. Deletion of mPGES-1 retards atherogenesis and limits aortic aneurysm formation in hyperlipidaemic mice. However, it does not predispose to thrombogenesis and has a limited impact on blood pressure compared to inhibition of COX-2. This occurs despite the potential of the suppressed PGE2 in affording cardioprotection via its EP2 and EP4 receptors. However, deletion of mPGES-1 permits rediversion of the PGH2 substrate to other PG synthases and augmented formation of PGI2 and PGD2 mitigates this effect. However, increased PGI2 may also attenuate relief of pain. Pain relief seems likely to be a nuanced indication for mPGES-1 inhibitors, but they have therapeutic potential in syndromes of cardiovascular inflammation, cancer and perhaps in neurodegenerative disease. However, as the products of substrate rediversion vary according to cell type, these drugs may have contrasting impact amongst individuals at varied stages of disease evolution.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: